Search
for
Sort by
Research 241–270 of 1000+
- Serum-Based Assessment of Alopecia Areata Response to Treatment Using ATR-FTIR Spectroscopy
- Annual Convention in the Time of COVID
- An unusual presentation of pilomatrixoma
- Advances in Bioprinting to Model Immune‐Mediated Skin Diseases
- Dermatology Patient Support Groups
- Immunopharmacological potential of Arctium lappa L. in immune-mediated skin diseases: A critical review of experimental and clinical evidence
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Avian-Inspired Analogies in Dermatology
- Animals in Dermatology
- Faculty Forum: Dermatology Residency and an Approach to the MD Examination: A Primer for Postgraduate Students
- Conference 2022, The Sequel
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Atypical Presentation of Lichen Planopilaris: Presentation of Two Cases and Review
- Use of Videodermatoscopy in Scalp Disorders
- Subject Index
- TONGUE, RED
- The Functional Organization of Cutaneous Low-Threshold Mechanosensory Neurons
- Advances in skin grafting and treatment of cutaneous wounds
- Cutaneous wound healing: recruiting developmental pathways for regeneration
- Cutaneous and Mucosal Lichen Planus: A Comprehensive Review of Clinical Subtypes, Risk Factors, Diagnosis, and Prognosis
- TRPA1 Modulates Mechanotransduction in Cutaneous Sensory Neurons
- Cutaneous Androgen Metabolism: Basic Research and Clinical Perspectives
- Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics
- Advances of Stem Cell Therapeutics in Cutaneous Wound Healing and Regeneration
- Interferon alfa-2a in the treatment of cutaneous T cell lymphoma
- Nonablative cutaneous remodeling using radiofrequency devices
- Cutaneous adverse effects of targeted therapies
- Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions
- Cutaneous signs in COVID ‐19 patients: A review
- Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma